PSCH Overview

Small-Cap Stocks Performance: Small-cap stocks have surged, with the Russell 2000 Index gaining 10.4% this month amid expectations of Fed rate cuts, while the U.S. economy shows resilience with a GDP growth of 2.8% in Q2, driven by consumer spending and business investment.

Sector Opportunities and Risks: Lower interest rates are expected to benefit sectors like real estate, consumer discretionary, and financial services, while small-cap stocks are viewed as safer investments during political or economic turmoil, particularly amidst ongoing global conflicts.

• A clinical-stage biotechnology company focusing on Tregs for inflammation and neuroinflammation treatments.
• Shares surged by 70% post-IPO, outperforming the Invesco S&P SmallCap Health Care ETF.

• Emphasizes a comprehensive approach over the traditional 'one disease – one target – one drug' model for neurodegenerative disorders.
• Moving towards combination approaches and biologics in line with the general biotech market trends.

• Lead investigational biologic product targeting ALS, FTD, Parkinson’s, and Alzheimer’s diseases.
• Combines low-dose interleukin-2 and CTLA4-Ig for a dual mechanism of action to restore Treg function and suppress pro-inflammatory cells.

• Targeting >50% of ALS patients initially, with plans for expansion into FTD.
• Differentiates from Biogen's product by aiming to treat all ALS patients and offering a different administration method.

• Sees COYA 302 as a versatile treatment option for various neurodegenerative conditions driven by immune imbalance and Treg dysfunction.
• Plans for additional clinical trials in Alzheimer’s, Parkinson’s, and FTD in the future.